Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • DMXAA (Vadimezan, AS-1404): Vascular Disrupting Agent for...

    2025-11-09

    DMXAA (Vadimezan, AS-1404): A Vascular Disrupting Agent for Advanced Cancer Biology Research

    Executive Summary: DMXAA (Vadimezan, AS-1404) is a potent vascular disrupting agent (VDA) and selective competitive inhibitor of DT-diaphorase (Ki = 20 μM, IC50 = 62.5 μM) with pronounced anti-cancer properties (Zhang et al., 2025). In murine models, administration at 25 mg/kg leads to rapid tumor vascular disruption and apoptosis in endothelial cells (Zhang et al., 2025). DMXAA blocks VEGFR2 signaling, thereby inhibiting angiogenesis and enhancing anti-tumor immune responses [internal]. The compound is insoluble in water/ethanol but dissolves in DMSO at ≥14.1 mg/mL, requiring specific handling protocols. This article reviews the molecular rationale, validated mechanisms, benchmarks, and practical integration of DMXAA for translational cancer research.

    Biological Rationale

    Vascular disrupting agents (VDAs) like DMXAA target tumor blood vessels, inducing rapid and selective vascular collapse. DMXAA acts primarily by inhibiting DT-diaphorase, an enzyme overexpressed in many cancers (ApexBio). Tumor endothelial cells are susceptible due to their high metabolic activity and reliance on VEGFR2-mediated signaling. By targeting the tumor microenvironment (TME), DMXAA not only causes direct cytotoxicity but also potentiates immune responses via the STING-JAK1 axis (Zhang et al., 2025). The compound’s selectivity and efficacy make it ideal for modeling tumor vasculature disruption and dissecting anti-angiogenic pathways [internal].

    Mechanism of Action of DMXAA (Vadimezan, AS-1404)

    • DT-diaphorase Inhibition: DMXAA is a selective competitive inhibitor of DT-diaphorase (Ki = 20 μM; IC50 = 62.5 μM) (ApexBio).
    • Induction of Apoptosis: It triggers apoptosis in tumor endothelial cells by releasing cytochrome c and activating caspase-3, leading to tumor necrosis (Zhang et al., 2025).
    • Anti-Angiogenic Activity: DMXAA blocks VEGFR2 signaling, inhibiting new blood vessel formation in tumors [internal].
    • STING Pathway Engagement: It modulates innate immune sensing by activating the STING-JAK1 axis in endothelial cells, promoting vessel normalization and immune cell infiltration (Zhang et al., 2025).
    • Cell Cycle Arrest: DMXAA arrests cancer cells in the G1 phase, inhibiting proliferation (ApexBio).

    This multi-modal mechanism uniquely positions DMXAA for systems-level interrogation of tumor vascular dynamics and immune interplay. For a systems biology perspective, see this comparative analysis, which DMXAA-focused mechanistic pathways in greater depth.

    Evidence & Benchmarks

    • DMXAA administration at 25 mg/kg in murine models induces significant tumor vascular disruption and apoptosis within 24 hours (Zhang et al., 2025, DOI).
    • Combined treatment with lenalidomide enhances anti-tumor efficacy, supporting synergistic protocols in preclinical studies (ApexBio, product page).
    • DMXAA blocks VEGFR2 phosphorylation, leading to reduced angiogenesis in human endothelial cell assays (internal, source).
    • STING agonist activity is confirmed by increased JAK1 phosphorylation and CD8+ T cell infiltration in tumor tissues (Zhang et al., 2025, DOI).
    • DMXAA is insoluble in water/ethanol but soluble in DMSO at ≥14.1 mg/mL; optimal storage at -20°C for several months maintains activity (ApexBio, product page).

    For a mechanistic deep dive, see this review, which this article updates by including recent findings on immune modulation.

    Applications, Limits & Misconceptions

    DMXAA (Vadimezan, AS-1404) is used extensively in cancer biology research, especially for:

    • Modeling vascular disruption and angiogenesis inhibition.
    • Studying apoptosis in tumor endothelial cells.
    • Investigating STING pathway activation and immune infiltration in tumor models.
    • Evaluating combinatorial strategies with immunomodulatory agents.

    While DMXAA demonstrates robust activity in murine and select preclinical models, translational efficacy in humans is limited by species-specific STING activation (Zhang et al., 2025). The compound is not suitable for clinical or diagnostic use in humans, is strictly for research purposes, and should not be interpreted as a direct proxy for clinical STING agonists.

    Common Pitfalls or Misconceptions

    • Species Specificity: DMXAA is a potent STING agonist in mice but not in human models due to STING structural divergence (Zhang et al., 2025).
    • Solubility Limitations: Insoluble in aqueous solvents; improper dissolution impairs bioactivity.
    • Not for Clinical Use: DMXAA is designated for research only and is not approved for diagnostic or therapeutic use.
    • Cell Line Variability: Differential DT-diaphorase expression may affect response; always verify target expression in cell models.
    • Extrapolation Error: Results from murine models may not directly predict human clinical outcomes.

    For an exploration of endothelial immunity and advanced anti-angiogenic strategies, see this perspective, which this article extends by focusing on workflow integration and benchmark data.

    Workflow Integration & Parameters

    • Preparation: Dissolve in DMSO at ≥14.1 mg/mL. Warm solution to 37°C for complete dissolution.
    • Storage: Store stock at -20°C; stable for several months.
    • Administration: Typical in vivo dose: 25 mg/kg in mouse models (intraperitoneal injection); adjust for experimental design.
    • Compatibility: DMXAA can be combined with immunomodulators (e.g., lenalidomide) for synergistic studies.
    • Controls: Include vehicle (DMSO) and positive/negative controls for apoptosis and angiogenesis endpoints.

    Refer to the A8233 kit product page for detailed solubility and handling protocols. For workflows employing systems-level analysis, see the comparative discussion at this article.

    Conclusion & Outlook

    DMXAA (Vadimezan, AS-1404) remains a vital tool in preclinical cancer research for dissecting tumor vasculature and immune pathways. Its unique dual action—vascular disruption and STING-dependent immune activation—offers powerful models for anti-angiogenic and immunotherapy research. However, species specificity and non-clinical status are critical boundaries for its application. Continued research into human-compatible analogs and combinatorial strategies will further elucidate the translational potential of VDAs. For future updates and comparative reviews, consult both recent literature and the ApexBio DMXAA page.